Comments to the FDA on Biosimilar Naming
Public Citizen issued comments to the Food and Drug Administration (FDA) concerning its draft guidance on the naming of biosimilar medications. The comments largely agree with the FDA’s proposals in the guidance, while urging the agency to engage in greater pharmacovigilance efforts and to assign identical names for interchangeable biosimilars, in order to facilitate their use.